George Kong

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

James Larkin, David R. Minor, Sandra P. D’Angelo et al. · Journal of Clinical Oncology · 2017 · 510 citations · Full text

Medicine, Oncology, Pharmacology +17

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Jeffrey S. Weber, Geoff Gibney, Ryan J. Sullivan et al. · The Lancet Oncology · 2016 · 335 citations

Medicine, Oncology, Pharmacology +16

Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling

Andrew Osborne, Tasneem Khatib, Lalana Songra et al. · Cell Death and Disease · 2018 · 169 citations · Full text

Medicine, Neurobiology, Ophthalmology +17

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 110 citations

Medicine, Pharmacology, Pharmacotherapy +11

Validation of a Tablet as a Tangent Perimeter

Algis J. Vingrys, Jessica Kate Healey, Sheryl Liew et al. · Translational Vision Science & Technology · 2016 · 81 citations · Full text

Medicine, Ophthalmology, Vision Science +15